Madrid, Spain | 23-25 October 2026

PRIME-ROSE partners will present a strong portfolio of scientific and policy-focused research at the ESMO Congress 2026 in Madrid, highlighting how collaborative European initiatives are advancing precision cancer medicine and expanding access to innovative treatments for patients with cancer.

Across poster and proffered paper sessions, investigators from PRIME-ROSE partner studies and related European initiatives will share new findings from precision oncology trials, drug repurposing programs, and implementation research. The presentations demonstrate the growing impact of cross-border collaboration in generating evidence for molecularly guided therapies beyond traditional indications.

Friday,23 October | Poster Session (15:15-16:00)

The session will feature results from several leading European precision oncology trials:

ProTarget (Denmark):

• 1032P - A Signal-Seeking Study of Niraparib Efficacy Outside Current Drug Label in Patients with Advanced Cancer: Results from the Danish ProTarget Precision Oncology Trial (Tina M. Kringelbach)
• 4292P - Multi-omics Identifies Predictive Markers for BRAF/MEK Inhibitors Used Outside Labelled Indications in Patients with BRAF-V600E Mutated Solid Tumors (Tine Oestergaard)

DETERMINE (UK):

•         1036P - Alectinibas a tumour-agnostic intervention for ALK fusion-positive cancers: The DETERMINE trial (Matthew G. Krebs)

FINPROVE (Finland):

•         4470P - First Readout from FINPROVE: Stage 1 Completed Cohorts (Katriina Jalkanen)

DRUP (The Netherlands):

•         4489P - Efficacy of panitumumab monotherapy in patients with advanced or metastatic RAS/RAF wild-type (wt) tumors: Results from the Drug Rediscovery Protocol (DRUP) (Aaltje E. Evertse)

Sunday,25 October | Proffered Paper Sessions

Two oral presentations will highlight the clinical impact and policy implications of precision oncology:

Session: Policy Room: Seville Auditorium – NCC at 10:15 - 11:45

• 3312O - When off-label beats on-label in oncology: 11 oncological drugs in The Netherlands that are used more off-label than on-label (Atse Huisman)

Session: CNS tumours  Room: Murcia Auditorium - Hall 3 at 10:15 -11:45

• 694O - Clinical benefit of matched targeted therapy in CNS tumors: results from 349 patients in IMPRESS-Norway (Pitt Niehusmann)

‍

Sunday,25 October | Poster Session (12:00-12:45)

PRIME-ROSE-related presentations will include:

PRIME-ROSE:

• 827P: Pertuzumab and Trastuzumab in HER2 overexpressed/ERBB2 amplified treatment refractory metastatic colorectal cancer. Merged data from patients treated in DRUP, FINPROVE, IMPRESS-Norway and ProTarget trials. (Rikke L. Eefsen)
• 3340P - Mapping Endpoints and Core Variables in European Precision Cancer Medicine (PCM) Trials for the Joint Action on PCM (Henk Van der Pol)
• 3356P - Academic drug repurposing: Opportunities and challenges of the revised EU Pharmaceutical Legislation in addressing unmet needs (Floor De Jong)

‍

Advancing Precision Oncology Through Collaboration

Together, these presentations reflect the shared ambition of PRIME-ROSE and its partners: generating robust evidence for precision oncology approaches, facilitating cross-border learning, and supporting more equitable access to innovative cancer treatments across Europe.

We look forward to engaging with colleagues and stakeholders in Madrid and discussing how collaborative research can help translate scientific discoveries into better outcomes for patients.

‍